The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

The present invention relates to an aromatic compound and a preparation method therefor and the use thereof. Specifically, disclosed are a compound as shown in the following general formula (I), or a tautomer, an enantiomer, a diastereomer or a racemate thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof. Also disclosed are a method for preparing the above compound and the use of same in the treatment of nervous system diseases.

The invention provides compounds represented by the general formula I

##STR00001##

wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.

The invention provides compounds represented by the general formula I

##STR00001##

wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.

The present invention relates inter alia to a compound of formula (I)

##STR00001##

wherein R.sub.1, R.sub.2 and R.sub.3, are as defined in the specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of fibrotic diseases or interstitial lung diseases, in particular idiopathic pulmonary fibrosis.

The present invention relates inter alia to a compound of formula (I)

##STR00001##

wherein R.sub.1, R.sub.2 and R.sub.3, are as defined in the specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of fibrotic diseases or interstitial lung diseases, in particular idiopathic pulmonary fibrosis.

This application provides a lithium-ion battery and an apparatus. The lithium-ion battery includes an electrode assembly and an electrolyte. The electrode assembly includes a positive electrode plate, a negative electrode plate, and a separator. A positive active material of the positive electrode plate includes Li.sub.x1Co.sub.y1M.sub.1-y1O.sub.2-z1Q.sub.z1, where 0.5≤x1≤1.2, 0.8≤y1≤1.0, 0≤z1≤0.1, M is selected from one or more of Al, Ti, Zr, Y, and Mg, and Q is selected from one or more of F, Cl, and S. The electrolyte contains an additive A that is a polynitrile six-membered nitrogen-heterocyclic compound with a relatively low oxidation potential. The lithium-ion battery has superb cycle performance and storage performance, especially under high-temperature and high-voltage conditions.

This application provides a lithium-ion battery and an apparatus. The lithium-ion battery includes an electrode assembly and an electrolyte. The electrode assembly includes a positive electrode plate, a negative electrode plate, and a separator. A positive active material of the positive electrode plate includes Li.sub.x1Co.sub.y1M.sub.1-y1O.sub.2-z1Q.sub.z1, where 0.5≤x1≤1.2, 0.8≤y1≤1.0, 0≤z1≤0.1, M is selected from one or more of Al, Ti, Zr, Y, and Mg, and Q is selected from one or more of F, Cl, and S. The electrolyte contains an additive A that is a polynitrile six-membered nitrogen-heterocyclic compound with a relatively low oxidation potential. The lithium-ion battery has superb cycle performance and storage performance, especially under high-temperature and high-voltage conditions.

The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them: ##STR00001##
wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.

This disclosure relates to aryl amidines of Formula I and their use as fungicides.

##STR00001##